Calcium Gluconate In Sodium Chloride is a drug owned by Hq Specialty Pharma Corp. It is protected by 2 US drug patents filed from 2018 to 2019 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 25, 2037. Details of Calcium Gluconate In Sodium Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10130646 | Calcium gluconate solutions in flexible containers |
Jul, 2037
(11 years from now) | Active |
| US10342813 | Calcium gluconate solutions in flexible containers |
Jul, 2037
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Calcium Gluconate In Sodium Chloride's patents.
Latest Legal Activities on Calcium Gluconate In Sodium Chloride's Patents
Given below is the list of recent legal activities going on the following patents of Calcium Gluconate In Sodium Chloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Dec, 2022 | US10342813 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 04 May, 2022 | US10130646 (Litigated) |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 28 Apr, 2021 | US10342813 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 09 Feb, 2021 | US10130646 (Litigated) |
| Patent Issue Date Used in PTA Calculation
Critical | 09 Jul, 2019 | US10342813 |
| Recordation of Patent Grant Mailed
Critical | 09 Jul, 2019 | US10342813 |
| Email Notification
Critical | 20 Jun, 2019 | US10342813 |
| Issue Notification Mailed
Critical | 19 Jun, 2019 | US10342813 |
| Dispatch to FDC | 12 Jun, 2019 | US10342813 |
| Application Is Considered Ready for Issue
Critical | 31 May, 2019 | US10342813 |
US patents provide insights into the exclusivity only within the United States, but
Calcium Gluconate In Sodium Chloride is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Calcium Gluconate In Sodium Chloride's family patents as well as insights into
ongoing legal events
on those patents.
Calcium Gluconate In Sodium Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Calcium Gluconate In Sodium Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 25, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Calcium Gluconate In Sodium Chloride Generic API suppliers:
Calcium Gluconate is the generic name for the brand Calcium Gluconate In Sodium Chloride. 4 different companies have already filed for the generic of Calcium Gluconate In Sodium Chloride, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Calcium Gluconate In Sodium Chloride's generic
About Calcium Gluconate In Sodium Chloride
Calcium Gluconate In Sodium Chloride is a drug owned by Hq Specialty Pharma Corp. It is used for treating high blood pressure and heart failure. Calcium Gluconate In Sodium Chloride uses Calcium Gluconate as an active ingredient. Calcium Gluconate In Sodium Chloride was launched by Hq Spclt Pharma in 2018.
Approval Date:
Calcium Gluconate In Sodium Chloride was approved by FDA for market use on 29 October, 2018.
Active Ingredient:
Calcium Gluconate In Sodium Chloride uses Calcium Gluconate as the active ingredient. Check out other Drugs and Companies using Calcium Gluconate ingredient
Treatment:
Calcium Gluconate In Sodium Chloride is used for treating high blood pressure and heart failure.
Dosage:
Calcium Gluconate In Sodium Chloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1GM/100ML (10MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 1GM/50ML (20MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 2GM/100ML (20MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
Calcium Gluconate In Sodium Chloride is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 25, 2037. Details of Calcium Gluconate In Sodium Chloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10130646 | Calcium gluconate solutions in flexible containers |
Jul, 2037
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Calcium Gluconate In Sodium Chloride's patents.
Latest Legal Activities on Calcium Gluconate In Sodium Chloride's Patents
Given below is the list of recent legal activities going on the following patents of Calcium Gluconate In Sodium Chloride.
| Activity | Date | Patent Number |
|---|---|---|
| | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Dec, 2022 | US10342813 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 04 May, 2022 | US10130646 (Litigated) |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 28 Apr, 2021 | US10342813 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 09 Feb, 2021 | US10130646 (Litigated) |
| Patent Issue Date Used in PTA Calculation
Critical | 09 Jul, 2019 | US10342813 |
| Recordation of Patent Grant Mailed
Critical | 09 Jul, 2019 | US10342813 |
| Email Notification
Critical | 20 Jun, 2019 | US10342813 |
| Issue Notification Mailed
Critical | 19 Jun, 2019 | US10342813 |
| Dispatch to FDC | 12 Jun, 2019 | US10342813 |
| Application Is Considered Ready for Issue
Critical | 31 May, 2019 | US10342813 |
US patents provide insights into the exclusivity only within the United States, but
Calcium Gluconate In Sodium Chloride is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Calcium Gluconate In Sodium Chloride's family patents as well as insights into
ongoing legal events
on those patents.
Calcium Gluconate In Sodium Chloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Calcium Gluconate In Sodium Chloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 25, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Calcium Gluconate In Sodium Chloride Generic API suppliers:
Calcium Gluconate is the generic name for the brand Calcium Gluconate In Sodium Chloride. 4 different companies have already filed for the generic of Calcium Gluconate In Sodium Chloride, with Amneal having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Calcium Gluconate In Sodium Chloride's generic
About Calcium Gluconate In Sodium Chloride
Calcium Gluconate In Sodium Chloride is a drug owned by Fresenius Kabi Usa Llc. It is used for treating high blood pressure and heart failure. Calcium Gluconate In Sodium Chloride uses Calcium Gluconate as an active ingredient. Calcium Gluconate In Sodium Chloride was launched by Fresenius Kabi Usa in 2017.
Approval Date:
Calcium Gluconate In Sodium Chloride was approved by FDA for market use on 15 June, 2017.
Active Ingredient:
Calcium Gluconate In Sodium Chloride uses Calcium Gluconate as the active ingredient. Check out other Drugs and Companies using Calcium Gluconate ingredient
Treatment:
Calcium Gluconate In Sodium Chloride is used for treating high blood pressure and heart failure.
Dosage:
Calcium Gluconate In Sodium Chloride is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2GM/100ML (20MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |
| 1GM/50ML (20MG/ML) | SOLUTION | Discontinued | INTRAVENOUS |